Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
A surgeon-led outpatient palliative care clinic for head and neck cancer patients demonstrated significant symptom improvement, prolonged survival, and high rates of home or hospice deaths, underscoring its value in multidisciplinary cancer
This study validates the MD Anderson Dysphagia Inventory (MDADI) as a reliable screening tool for VFSS-graded swallowing impairment in head and neck cancer patients and proposes a concise four-item version to optimize clinical utility.
Neoadjuvant chemoimmunotherapy significantly improves pathologic complete and major responses compared to immunotherapy alone in resectable head and neck squamous cell carcinoma, suggesting a promising avenue to improve treatment outcomes.
A phase 2 trial shows pembrolizumab combined with low-dose quad-shot radiotherapy yields encouraging response rates and survival outcomes in recurrent, unresectable head and neck squamous cell carcinoma.
The addition of perioperative pembrolizumab to standard care improves event-free survival in locally advanced head and neck squamous cell carcinoma, with cost-effectiveness dependent on PD-L1 combined positive score.
This review synthesizes evidence on patients’ perceptions of telehealth for head and neck cancer surveillance, highlighting barriers, benefits, and the potential of hybrid models to improve acceptability post-treatment.
A genetic study reveals that higher blood manganese levels are significantly associated with increased risks of oral cavity and HPV-positive oropharyngeal squamous cell carcinomas, suggesting a novel biomarker and potential target for preve
This review synthesizes evidence on factors influencing delays in postoperative radiotherapy for head and neck cancer in rural settings, emphasizing communication, coordination, and community resources to inform strategies that improve care
This study found that patient-reported speech/voice and related head-and-neck symptoms can help predict hypoglossal neuropathy risk after oropharyngeal cancer treatment, supporting earlier surveillance with the MDASI-HN-NERVE score.
In patients with head and neck cancer, living in the most socioeconomically disadvantaged areas was associated with poorer pretreatment head and neck cancer–specific quality of life, while associations with other quality-of-life domains wer
In a retrospective cohort of 362 head and neck free tissue transfer patients, routine hospitalist involvement was associated with fewer transfers to a higher level of care, without significant effects on length of stay, readmission, or 90-d
In advanced head and neck squamous cell carcinoma, pretreatment weight loss and low prognostic nutritional index were linked to shorter progression-free survival after immunotherapy, while baseline BMI was not predictive.
A large claims-based study reveals pembrolizumab dominates immunotherapy prescribing for head and neck cancer, with minimal usage growth since FDA approval. Immune-related adverse events occurred in 41.2% of patients, linked to specific com
This study identifies clinicopathologic factors linked to pre- and postoperative levels of circulating tumor HPV DNA (ctHPVDNA) in HPV-mediated oropharyngeal cancer patients treated with upfront surgery, offering insights for disease monito
This clinical analysis of 136 patients highlights that head and neck metastases often serve as the primary manifestation of infraclavicular cancers, emphasizing the diagnostic value of cervical lymph nodes.
The ELAN-RT trial demonstrates that hypofractionated split-course radiotherapy is non-inferior to standard fractionation for 6-month locoregional response in frail older patients, providing a less toxic alternative, though standard therapy
This review analyzes the Phase 3 NIVOPOST-OP trial, demonstrating that adding nivolumab to postoperative chemoradiotherapy significantly improves disease-free survival in high-risk SCCHN patients, establishing a potential new therapeutic st
A large-scale cohort study of 47,365 head and neck cancer patients reveals a significant market shift toward pembrolizumab and a 41.2% incidence of immune-related adverse events, though severe toxicities remain rare and are linked to specif
This article examines the clinical accuracy of Sentinel Lymph Node Biopsy for head and neck Merkel cell carcinoma, highlighting a significant false-negative rate and identifying risk factors that necessitate more personalized treatment stra
A new study reveals that ‘tumor-informed’ blood tests can detect recurring head and neck cancer months before traditional scans, offering a critical window for intervention in high-risk patients.